Efficacy and Safety of Seladelpar, a Selective Peroxisome Proliferator-Activated Receptor Delta Agonist, in Primary Biliary Cholangitis: 52-Week Analysis of an Ongoing International, Randomized, Dose Ranging Phase 2 Study

Bowlus CL, Neff GW, Aspinall R, Galambos MR, Goel A, Hirschfield G, Kremer A, Mayo MJ, Swain MG, Borg B, Doerffel Y, Gordon SC, Harrison SA, Jones D, Thuluvath PJ, Levy C, Sheridan DA, Stanca CM, Bacon BR, Berg C, Hassanein TI, Odin J, Shiffman ML, Thorburn D, Vierling JM, Bernstein D, Buggisch P, Corless L, Landis CS, Peyton AL, Shah HA, Woerns MA, Gitlin N, Steinberg A, Bergheanu S, Amato G, Choi YJ, Rosenbusch S, Varga M, Mcwherter C, Boudes P (2018)

Publication Type: Conference contribution

Publication year: 2018

Journal

Book Volume: 68

Pages Range: 1446A-1447A

Journal Issue: 6

DOI: 10.1016/s0168-8278(18)30429-x

Authors with CRIS profile

Involved external institutions

University of Miami United States (USA) (US) CymaBay Therapeutic United States (USA) (US) Eastern Pennsylvania Gastroenterology and Liver Specialists United States (USA) (US) ifi-Institut für interdisziplinäre Medizin Germany (DE) University of Washington United States (USA) (US) University Hospitals Plymouth NHS Trust United Kingdom (GB) University of Texas Southwestern Medical Center (UT Southwestern) United States (USA) (US) Southern Therapy and Advanced Research LLC United States (USA) (US) Johannes Gutenberg-Universität Mainz (JGU) Germany (DE) Portsmouth Hospitals NHS Trust United Kingdom (GB) Newcastle University United Kingdom (GB) Atlanta Gastroenterology Associates United States (USA) (US) Stanford University United States (USA) (US) Henry Ford Health System (HFHS) United States (USA) (US) Royal Free Hospital United Kingdom (GB) Hull and East Yorkshire Hospitals NHS Trust United Kingdom (GB) Universitätsklinikum Tübingen Germany (DE) UC Davis Medical Center United States (USA) (US) New York University (NYU) United States (USA) (US) Southern California Liver Centers United States (USA) (US) Pinnacle Clinical Research United States (USA) (US) Saint Louis University (SLU) United States (USA) (US) University Health Network (UHN) Canada (CA) University of Birmingham United Kingdom (GB) Lakewood Ranch Cancer Center United States (USA) (US) Donald and Barbara Zucker School of Medicine at Hofstra/Northwell United States (USA) (US) Bon Secours Liver Institute of Richmond United States (USA) (US) Houston Texas Medical Center United States (USA) (US) Icahn School of Medicine at Mount Sinai United States (USA) (US) University of Calgary Canada (CA) Mercy Medical Center United States (USA) (US) Charité - Universitätsmedizin Berlin Germany (DE) Saberg Clinical Research Netherlands (NL)

How to cite

APA:

Bowlus, C.L., Neff, G.W., Aspinall, R., Galambos, M.R., Goel, A., Hirschfield, G.,... Boudes, P. (2018). Efficacy and Safety of Seladelpar, a Selective Peroxisome Proliferator-Activated Receptor Delta Agonist, in Primary Biliary Cholangitis: 52-Week Analysis of an Ongoing International, Randomized, Dose Ranging Phase 2 Study. (pp. 1446A-1447A).

MLA:

Bowlus, Christopher L., et al. "Efficacy and Safety of Seladelpar, a Selective Peroxisome Proliferator-Activated Receptor Delta Agonist, in Primary Biliary Cholangitis: 52-Week Analysis of an Ongoing International, Randomized, Dose Ranging Phase 2 Study." 2018. 1446A-1447A.

BibTeX: Download